Skip to main content

Advertisement

Table 2 Comparison of clinical and pathological characteristics of carriers and non-carriers tested at Oslo University Hospital Ullevål (OUH-U)

From: Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers

  BRCA 1/2 carriers (n = 13) Non-carriers (n = 427) p-values
Below 40 years 5 (38.5%) 24 (5.6%)  
Below 50 years 10 (76.9%) 106 (24.8%)  
Below 60 years 13 (100%) 222 (52.0%)  
Age at diagnosis
 Mean (95% CI) 42 (36.1-47.9) 57.9 (56.8-59.1) <0.001
 Median (range) 43 (26-58) 58 (23-93)  
Predictive test criteria fulfilled 4 (30.8%) 49 (11.5%) 0.035
Stringent NBCG criteria fulfilled 12 (92.3%) 130 (30.4%) <0.001
TNM (n = 13) (n = 422)  
 T1 5 (38.5%) 261 (61.8%)  
 T2 5 (38.5%) 121 (28.7%) 0.396
 T3 2 (15.3%) 26 (6.2%)  
 T4 1 (7.7%) 13 (3.1%)  
 N0 8 (61.5%) 295 (72.0%)  
 N1 2(15.4%) 82 (19.4%) 0.078
 N2 3(23.1%) 24 (5.7%)  
 N3 0 12 (2.8%)  
 Distant metastasis 0 2 (0.5%) 0.76
Grade (n = 13) (n = 419)  
 1 0 101 (24.1%) 0.001
 2 4 (30.8%) 211 (50.4%)  
 3 9 (69.2%) 107 (25.5%)  
Estrogen receptor status (n = 13) (n = 423)  
 Positive 7 (53.8%) 371 (87.7%) <0.001
 Negative 6 (46.2%) 52 (12.3%)  
Progesterone receptor status (n = 13) (n = 422) 0.045
 Positive 5 (38.5%) 276 (65.4%)  
 Negative 8 (61.5%) 146 (34.6%)  
HER2 status (n = 13) (n = 423)  
 Positive 2 (15.4%) 57 (13.5%) 0.84
 Negative 11 (84.6%) 366 (86.5%)  
Triple negative breast cancer (n = 13) (n = 422)  
5 (38.5%) 30 (7.1%) <0.001
Ki67 (n = 13) (n = 412)  
 Mean (95% CI) 59 (45.3-72.8) 31.3 (29-33) <0.001
  < 30% activity 11 (84.6%) 182 (44.1%) 0.004
  1. NBCG Norwegian Breast Cancer Group
  2. TNM Scoring of tumors according to the TNM Classification of Malignant Tumors
  3. T Size of original tumor
  4. N Involvement of regional lymph nodes
  5. M Distant metastasis